pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Migranal
drug
save

Migranal

Marketedupdated 3mo ago
by Bausch Health US LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • drugdihydroergotamine mesylate1 co-mentions · 1 sources
  • tagRecall1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Migranal

  • phase1A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adultscompletedn=44

Patent cliff

source: FDA Orange Book
first barrier falls
Apr 30, 2028
~1.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (16)

  • Oct 12, 2041formulationUS 11744967
  • Oct 12, 2041formulationUS 12102754
  • Dec 11, 2039formulationUS 10758532
  • Dec 11, 2039formulationUS 12263162
  • Feb 26, 2039formulationUS 10532049
  • Feb 26, 2039formulationUS 11304942
  • Feb 26, 2039method-of-use (U-4188)US 11819501
  • Feb 26, 2039formulationUS 12533351
  • Jan 4, 2039method-of-use (U-3218)US 11185497
  • Aug 4, 2037formulationUS 10792253
  • Aug 4, 2037formulationUS 11872314
  • Nov 5, 2036formulationUS 11266799
  • Mar 17, 2033formulationUS 9919117
  • Jan 23, 2033formulationUS 10940278
  • Dec 25, 2032formulationUS 10507295
  • Sep 5, 2032formulationUS 9550036

FDA exclusivities (1)

  • Apr 30, 2028NPNP1.7y

News(0)

no news has mentioned this drug yet

brand
Migranal
generic
dihydroergotamine mesylate
indication
Migraine
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 52m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?